Karyopharm Therapeutics Inc (KPTI), Ambit Biosciences Corp (AMBI) and BioDelivery Sciences International, Inc. (BDSI): Foresite Capital Management’s Top Picks

0

Foresite Capital Management, LLC has released its quarterly report. In this article we will briefly review its top three picks in the latest report. Three picks by Foresite Capital Management are Karyopharm Therapeutics Inc (NASDAQ:KPTI), Ambit Biosciences Corp (NASDAQ:AMBI) and BioDelivery Sciences International, Inc. (NASDAQ:BDSI).

The biggest position held by Foresite Capital is Karyopharm Therapeutics Inc (NASDAQ:KPTI). The fund management firm owns 1077124 shares the company worth $37 million. Last quarter, Foresite Capital had 1,377,410 shares of Karyopharm Therapeutics Inc (NASDAQ:KPTI) worth $64 million. This shows a clear decrease in investment by the fund manager in the company. Among other top shareholders of Karyopharm Therapeutics Inc (NASDAQ:KPTI) include Zach Schreiber’s PointState Capital and Paul Tudor’s Tudor Investment Corporation. The company recorded its last purchase in May 2014 whereas Ltd Chione sold its stock recently at around $43 per share.

The second biggest position held by Foresite Capital is Ambit Biosciences Corp (NASDAQ:AMBI). It has 2,079,569 shares of the biosciences company worth $32 million. Last quarter, the firm had 2,079,569 shares of Ambit Biosciences Corp (NASDAQ:AMBI) worth $14 million. This shows a clear depletion in the investment. Among other notorious shareholders of Ambit Biosciences Corporation include Dennis Purcell’s Aisling Capital. The company recorded its last purchase back in 2013.

The third biggest position in Foresite Capital is BioDelivery Sciences International, Inc. (NASDAQ:BDSI). It has 690,000 shares of the biotech company worth $11 million. Last quarter, Foresite had 700,000 of the same company worth $8 million. This depicts that the company is decreasing its investment in the biotech sector. Thomas Bailard’s Bailard Inc and James E. Flynn’s Deefield Management are the famous shareholders of BioDelivery Sciences International, Inc. (NASDAQ:BDSI). The company recorded its last purchase in Septembr this year. It was sold by Andrew Finn at $15 per share price.

Suggested Articles:

Best Paying Medical Specialties

Best Small Tech Companies

Share.